CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 150 enrolled
Drug / intervention
Iloprost +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03111212
NCT03111212Phase 3Completed
CompareCT.gov

Therapeutic Iloprost for the Treatment of Acute Respiratory Distress Syndrome (ARDS) (the ThIlo-Trial)

University Hospital Tuebingen·interventional·Posted Apr 12, 2017·Updated Dec 30, 2021

In Brief

A Phase 3 clinical trial evaluating Iloprost and control for Respiratory Distress Syndrome, Adult. Completed, enrolled 150 participants across 1 site.

Detailed Summary

The patients will be randomized into one of two groups. Both groups will receive standard care as is state of the art. The intervention group will receive Iloprost nebulized as inhalative therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Distress Syndrome, Adult
CountriesGermany
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedApr 12, 2017
Enrollment StartJun 25, 2019
Primary CompletionMay 14, 2021
Study CompletionAug 14, 2021
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.2 years ago

Interventions

Iloprostdrug

Iloprost nebulized

controldrug

sodium chloride 0,9% nebulized